PTC Therapeutics Announces FDA Acceptance And Priority Review For Vatiquinone NDA For The Treatment Of Children And Adults With Friedreich's Ataxia
PDUFA target action date of Aug. 19, 2025 - WARREN, N.J., Feb. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced ...